Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of colon cancer.

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer. The company said patients who took its experimental drug favezelimab in combination with Keytruda did not show significant improvement in overall survival compared to standard-of-care treatment.

Merck (NYSE:MRK) announced Wednesday that a Phase 3 trial designed to test its anti-PD-1 therapy Keytruda (pembrolizumab) as part of a combination regimen in patients with a type of colorectal cancer didn’t reach the primary endpoint.